NRx Logo
  • Our Company
  • Our Therapeutic Focus
    • Our Focus on the Brain
    • Bipolar Depression & Suicidality
    • Post-Traumatic Stress Disorder
  • Our Science
    • Our Clinical Approach
    • NRX-100/NRX-101
    • Mechanism of Action
    • NMDA & 5HT2A receptors
    • Publications & Literature
  • Pipeline
  • Investors / Media
  • Investor Relations
  • Presentation
  • Clinical Trials
  • Search

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Analyst Coverage
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Analyst Coverage
  • IR Calendar
  • Email Alerts
May 25, 2021 6:48am EDT

NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

Apr 28, 2021 2:12pm EDT

NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia

Apr 26, 2021 9:35am EDT

Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team

Apr 19, 2021 3:57pm EDT

NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development

Apr 06, 2021 1:01am EDT

NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

Mar 29, 2021 1:05am EDT

/C O R R E C T I O N -- NeuroRx/

Mar 26, 2021 9:35am EDT

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure

Mar 19, 2021 5:28pm EDT

UPDATE: NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COVID-19 (AVICOVID-2)

Mar 09, 2021 10:19am EST

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

Feb 23, 2021 1:11pm EST

NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint

  • arrow_back
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 16
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
NRx
  • Home
  • Our Company
  • Our Science
  • Pipeline
  • News & Media
  • Resources & Patient Stories
  • Investor Relations
  • Careers
  • Contact Us
  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin
  • Forward Looking Statement
  • Privacy Policy
  • Terms of Use
  • © 2022 NRx Pharmaceuticals, Inc.

  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin